Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells [PDF]
, 2015 Sorafenib, a tyrosine kinase inhibitor, has been demonstrated to exert anti-tumor effects. However, the molecular mechanisms underlying its effects on bladder cancer remain unknown.
AMANTINI, Consuelo +11 more
core +7 more sources
Mutation of the co-chaperone Tsc1 in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity [PDF]
, 2019 The molecular chaperone Heat shock protein 90 (Hsp90) is essential for the folding, stability, and activity of several drivers of oncogenesis. Hsp90 inhibitors are currently under clinical evaluation for cancer treatment, however their efficacy is ...
Backe, Sarah J +11 more
core +1 more source
SnapShot: Bladder Cancer [PDF]
Cancer Cell, 2018 Bladder cancers, the majority of which are urothelial carcinoma, are the most common urinary tract cancers. There are two major disease types, muscle-invasive and non-muscle-invasive, with distinct pathogenesis pathways, molecular features, and clinical outcomes.
Hurst, C, Rosenberg, J, Knowles, M
openaire +3 more sources
Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer [PDF]
, 2017 YesOsteopontin (OPN) plays an important role in cancer progression, however its prognostic significance and its downstream factors are largely elusive.
El-Tanani, Mohamed +8 more
core +4 more sources
UBC®Rapid Test for detection of carcinoma in situ for bladder cancer [PDF]
, 2017 UBC®Rapid Test is a test that detects fragments of cytokeratins 8 and 18 in urine. We present results of a multicentre study measuring UBC®Rapid Test in bladder cancer patients and healthy controls with focus on carcinoma in situ (CIS) and high-grade ...
Barski, Dimitri +6 more
core +1 more source
Immunotherapy for bladder cancer
Research and Reports in Urology, 2015 It is nearly 40 years since Bacillus Calmette-Guérin (BCG) was first used as an immunotherapy to treat superficial bladder cancer. Despite its limitations, to date it has not been surpassed by any other treatment. As a better understanding of its mechanism of action and the clinical response to it have evolved, some of the questions around optimal ...
James S.A. Green +3 more
openaire +6 more sources
Cancer incidence estimation from mortality data: a validation study within a population-based cancer registry [PDF]
Population Health Metrics, Volume 19, 18, 2021We assessed the validity of one of the most frequently used methods to estimate cancer incidence, on the basis of cancer mortality data and the incidence-to-mortality ratio IMR, the IMR method. Using the previous 15 year cancer mortality time series, we derived the expected yearly number of cancer cases in the period 2004 to 2013 for six cancer sites ...
arxiv +1 more source
Histopathology, 2010 Proctor I, Stoeber K & Williams G H (2010) Histopathology 57, 1–13 Biomarkers in bladder cancerCancer biomarkers provide an opportunity to diagnose tumours earlier and with greater accuracy. They can also identify those patients most at risk of disease recurrence and predict which tumours will respond to different therapeutic approaches.
Ian Proctor +2 more
openaire +4 more sources
The influence of glutathione S-transferases M1 and M3 on the development of bladder cancer [PDF]
Problem: Cigarette smoking is the most important risk factor of transitional cell carcinoma of the urinary bladder. The effect of the glutathione S- transferases M1 (GSTM1) and M3 (GSTM3) on the influence of this risk factor was investigated.
Bolt, Hermann M. +3 more
core
A glance at imaging bladder cancer. [PDF]
, 2018 Purpose: Early and accurate diagnosis of Bladder cancer (BCa) will contribute extensively to the management of the disease. The purpose of this review was to briefly describe the conventional imaging methods and other novel imaging modalities used for ...
Halpern, Ethan J. +4 more
core +1 more source